Search

Your search keyword '"Newberry, Kate J."' showing total 181 results
Start Over Author "Newberry, Kate J."
Sorry, I don't understand your search. ×
181 results on '"Newberry, Kate J."'

4. Supplementary Table 1 from In Vitro and In Vivo Therapeutic Efficacy of Carfilzomib in Mantle Cell Lymphoma: Targeting the Immunoproteasome

Author

Zhang, Liang, primary, Pham, Lan V., primary, Newberry, Kate J., primary, Ou, Zhishuo, primary, Liang, Rong, primary, Qian, Jianfei, primary, Sun, Luhong, primary, Blonska, Marzenna, primary, You, Yun, primary, Yang, Jing, primary, Lin, Xin, primary, Rollo, Alex, primary, Tamayo, Archito T., primary, Lee, John, primary, Ford, Richard J., primary, Zhao, Xiurong, primary, Kwak, Larry W., primary, Yi, Qing, primary, and Wang, Michael, primary

Published
2023
Full Text
View/download PDF

5. Supplementary Figure 1 from In Vitro and In Vivo Therapeutic Efficacy of Carfilzomib in Mantle Cell Lymphoma: Targeting the Immunoproteasome

Author

Zhang, Liang, primary, Pham, Lan V., primary, Newberry, Kate J., primary, Ou, Zhishuo, primary, Liang, Rong, primary, Qian, Jianfei, primary, Sun, Luhong, primary, Blonska, Marzenna, primary, You, Yun, primary, Yang, Jing, primary, Lin, Xin, primary, Rollo, Alex, primary, Tamayo, Archito T., primary, Lee, John, primary, Ford, Richard J., primary, Zhao, Xiurong, primary, Kwak, Larry W., primary, Yi, Qing, primary, and Wang, Michael, primary

Published
2023
Full Text
View/download PDF

6. Data from In Vitro and In Vivo Therapeutic Efficacy of Carfilzomib in Mantle Cell Lymphoma: Targeting the Immunoproteasome

Author

Zhang, Liang, primary, Pham, Lan V., primary, Newberry, Kate J., primary, Ou, Zhishuo, primary, Liang, Rong, primary, Qian, Jianfei, primary, Sun, Luhong, primary, Blonska, Marzenna, primary, You, Yun, primary, Yang, Jing, primary, Lin, Xin, primary, Rollo, Alex, primary, Tamayo, Archito T., primary, Lee, John, primary, Ford, Richard J., primary, Zhao, Xiurong, primary, Kwak, Larry W., primary, Yi, Qing, primary, and Wang, Michael, primary

Published
2023
Full Text
View/download PDF

7. Abstract OT3-23-01: VELA: A first-in-human phase 1/2 study of BLU-222, a potent, selective cyclin-dependent kinase (CDK) 2 inhibitor in patients with cyclin E1 gene (CCNE1)-amplified or CDK4/6 inhibitor-resistant advanced solid tumors

Author

Patel, Manish R, primary, Juric, Dejan, additional, Henick, Brian S, additional, Moore, Kathleen N, additional, Do, Doreen, additional, Chapman, Joshua, additional, Zhang, Hui, additional, Roche, Maria, additional, Newberry, Kate J, additional, Rinne, Mikael, additional, and Yap, Timothy A, additional

Published
2023
Full Text
View/download PDF

15. Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1/2 clinical trial

Author

Wang, Michael, Fayad, Luis, Wagner-Bartak, Nicolaus, Zhang, Liang, Hagemeister, Fredrick, Neelapu, Sattva S, Samaniego, Felipe, McLaughlin, Peter, Fanale, Michelle, Younes, Anas, Cabanillas, Fernando, Fowler, Nathan, Newberry, Kate J, Sun, Luhong, Young, Ken H, Champlin, Richard, Kwak, Larry, Feng, Lei, Badillo, Maria, Bejarano, Maria, Hartig, Kimberly, Chen, Wendy, Chen, Yiming, Byrne, Catriona, Bell, Neda, Zeldis, Jerome, and Romaguera, Jorge

Published
2012
Full Text
View/download PDF

17. Crystal structure of the Bacillus subtilis anti-alpha, global transcriptional regulator, Spx, in complex with the [alpha] C-terminal domain of RNA polymerase

Author

Newberry, Kate J., Nakano, Shunji, Zuber, Peter, and Brennan, Richard G.

Subjects
Bacillus subtilis -- Genetic aspects, Genetic transcription -- Research, Crystals -- Structure, Crystals -- Research, Science and technology
Abstract

Spx, a global transcription regulator in Bacillus subtilis, interacts with the C-terminal domain of the [alpha] subunit ([alpha]CTD) of RNA polymerase to control gene expression under conditions of disulfide stress, which is sensed by disulfide bond formation between Spx residues C10 and C13. Here, we describe the crystal structure of the B. subtilis [alpha]CTD bound to oxidized Spx. Analysis of the complex reveals interactions between three regions of 'antialpha' Spx and helix [alpha]1 and the '261' determinant of [alpha]CTD. The former contact could disrupt the interaction between [alpha]CTD and activator proteins or alter the DNA-bound conformation of [alpha]CTD, thereby repressing activator-stimulated transcription. Binding to the 261 determinant would prevent interaction between [alpha]CTD and region 4 of [[sigma].sup.A]. Intriguingly, the Spx disulfide bond is far from the [alpha]CTD--Spx interface, suggesting that Spx regulates transcription allosterically or through the redox-dependent creation or destruction of binding sites for additional components of the transcription machinery. ArsC family | global transcription regulation | oxidative/disulfide stress

Published
2005

20. Foreign tax credit limitations and capital structure decisions

Author

Newberry, Kate J.

Subjects
International business enterprises -- Securities, Foreign tax credit -- Research, Debt financing (Corporations) -- Research, Banking, finance and accounting industries, Business
Abstract

A study was conducted to further investigate the impact of foreign tax credit restrictions on organizational capital structure decisions using data gathered on 339 public offerings by multinationals of domestic debt, common stock and preferred stock from 1988-1991. New evidence suggests that foreign tax credit limitations encourage US multinationals to decrease their domestic debt by replacing this with both common and preferred stock financing. The results also indicate that larger multinationals are more likely to use preferred stock as an alternative funding option while smaller firms are more likely to select common stock. Further, the results overcome confounding variables linked with total measures of capital account changes.

Published
1998

28. Survival Outcome of Patients with Acute Myeloid Leukemia Transformed from Myeloproliferative Neoplasms

Author

Chihara, Dai, primary, Kantarjian, Hagop M., additional, Newberry, Kate J, additional, Ravandi, Farhad, additional, Daver, Naval G., additional, Bose, Prithviraj, additional, DiNardo, Courtney D., additional, Pemmaraju, Naveen, additional, Kadia, Tapan M., additional, Borthakur, Gautam, additional, Konopleva, Marina, additional, Garcia-Manero, Guillermo, additional, Popat, Uday R., additional, Cortes, Jorge E., additional, and Verstovsek, Srdan, additional

Published
2016
Full Text
View/download PDF

33. Dysregulation of microRNA cluster miR-29 in fibrocytes from patients with JAK2V617F-positive primary myelofibrosis

Author

Božinović, Ksenija, Manshouri, Taghi, Estrov, Zeev, Pilling, Darrell, Knez, Liza, Newberry, Kate J, Bueso-Ramos, Carlos E, Post, Sean, Verstovsek, Srdan, Kantarjian, Hagop, Labar, Boris, Nemet, Damir, and Verstovsek, Srdan

Subjects
microRNA, MPN, CD14+ cells
Abstract

Myeloproliferative neoplasms (MPN) are a class of stem cell–derived hematologic malignancies, characterized by an expansion of one or more myeloid lineages with resulting bone marrow (BM) hypercellularity. A gain-of-function mutation in JAK2, detected in most patients with MPN, induces constitutive activation of JAK2, stimulation of downstream signaling pathways, and activation of several cytokine and growth factor genes. Recent reports have linked tissue fibrosis, such as pulmonary fibrosis, end-stage liver or kidney disease, heart disease and autoimmune disorder to fibrocytes, spindle-shaped fibroblast-like cells that differentiate from a subpopulation of CD14+ monocytes. We therefore investigated changes in the expression of several microRNAs (miR-16, 21, 29a, 29b1, 29b2, 29c, 155, 181a, and 451) which are involved in a variety of biological processes, including cell cycle regulation, differentiation, and development in cultured fibrocytes from patients with primary myelofibrosis. Bone marrow mononuclear cells (MNC) from twenty eight primary myelofibrosis patients and nine normal control bone marrow samples were cultured, and the resulting fibrocytes were used for this study. Using qRT- PCR we found that the levels of miR-16 (P=0.0122), and miR-21 were significantly higher in PMF patients than in normal controls. Expression level of miR-29-b1 and -b2 were lower (P= 0.0007, P= 0.0001) in PMF patients ; however, the expression of miR29-c was higher(P= 0.0028). Dysregulation of miR-29 has been associated with coronary artery fibrosis and we conclude that miR-29 might play a role in bone marrow fibrosis and represent a potential therapeutic target.

Published
2015

34. Pentraxin‐3 plasma levels correlate with tumour burden and overall survival in patients with primary myelofibrosis.

Author

Veletic, Ivo, Manshouri, Taghi, Newberry, Kate J., Garnett, Jeannine, Verstovsek, Srdan, and Estrov, Zeev

Subjects
MYELOFIBROSIS, PENTRAXINS, ACUTE phase proteins
Abstract

The article offers information on the correlation between pentraxin (PTX3) plasma levels and parameters of tumour burden. It mentions that PTX3 plasma levels were significantly higher in Primary myelofibrosis (PMF) patients than in healthy; and also mentions that both covariates, PTX3 and C-reactive protein (CRP), independently predicted PMF patients' overall survival.

Published
2019
Full Text
View/download PDF

35. Role of neoplastic monocyte-derived fibrocytes in primary myelofibrosis

Author

Verstovsek, Srdan, primary, Manshouri, Taghi, additional, Pilling, Darrell, additional, Bueso-Ramos, Carlos E., additional, Newberry, Kate J., additional, Prijic, Sanja, additional, Knez, Liza, additional, Bozinovic, Ksenija, additional, Harris, David M., additional, Spaeth, Erika L., additional, Post, Sean M., additional, Multani, Asha S., additional, Rampal, Raajit K., additional, Ahn, Jihae, additional, Levine, Ross L., additional, Creighton, Chad J., additional, Kantarjian, Hagop M., additional, and Estrov, Zeev, additional

Published
2016
Full Text
View/download PDF

36. Efficacy and Safety of Pegylated Interferon Alpha-2a in Patients with Essential Thrombocythemia and Polycythemia Vera: Results after a Median 7-Year Follow-up of a Phase 2 Study

Author

Masarova, Lucia, primary, Verstovsek, Srdan, additional, Patel, Keyur P., additional, Newberry, Kate J, additional, Cortes, Jorge E., additional, Borthakur, Gautam, additional, Konopleva, Marina, additional, Estrov, Zeev, additional, and Kantarjian, Hagop M., additional

Published
2015
Full Text
View/download PDF

44. Histomorphological responses after therapy with pegylated interferon a-2a in patients with essential thrombocythemia (ET) and polycythemia vera (PV).

Author

Masarova, Lucia, Cameron Yin, C., Cortes, Jorge E., Konopleva, Marina, Borthakur, Gautam, Newberry, Kate J., Kantarjian, Hagop M., Bueso-Ramos, Carlos E., and Verstovsek, Srdan

Subjects
INTERFERON alpha, THROMBOCYTOPENIA treatment, THROMBOCYTOSIS, PATIENTS, THERAPEUTICS
Abstract

Background: Pegylated interferon alfa-2a (PEG-IFN-α-2a) is a potent immunomodulating agent capable of inducing high rate of hematologic and even complete molecular remission in patients with essential thrombocythemia (ET) and polycythemia vera (PV). We recently reported results of a phase 2 trial of PEG-IFN-α-2a in 83 patients with ET and PV after a median follow-up of 83 months. Here we report an analysis of bone marrow (BM) responses in these patients. Methods: Among 83 patients, 58 (70%, PV 25, ET 31) had evaluable BM samples. BM responses and fibrosis grading were defined according to the International Working Group for Myeloproliferative Neoplasms Research and Treatment, and the European Consensus on grading of BM fibrosis, respectively. BM was assessed prior to enrollment, and every 6-24 months while on therapy in all patients, and after therapy discontinuation in some patients. Results: The median age of analyzed 58 patients was 52 years, and 29% were males. After a median follow-up of 84 months, 32 patients are still on study. Hematologic (HR) and molecular responses (MR) were seen in 93 and 69% patients, respectively. Twenty-nine patients (50%) had a BM response, including 13 (22%) with a complete BM response (BM-CR). Moreover, 13 patients (22%) have experienced complete resolution of bone marrow reticulin fibrosis. Patients with BM response had higher duration of HR and MR, and lower discontinuation rate. Furthermore, patients with BM-CR had a higher probability of complete MR. The median duration of BM-CR was 30 months, and 9 patients have maintained their BM-CR (69%), including five who have maintained their response after discontinuation of therapy. Despite this observation, the pattern of HR, MR and BM response, their durability and interrelation was heterogeneous. Conclusions: Our results show the ability of PEG-IFN-á-2a to induce complete BM responses in a subset of ET and PV patients, but its correlation with durable clinically relevant treatment benefit warrants further investigation. [ABSTRACT FROM AUTHOR]

Published
2017
Full Text
View/download PDF

46. In Vitro and In Vivo Therapeutic Efficacy of Carfilzomib in Mantle Cell Lymphoma: Targeting the Immunoproteasome

Author

Zhang, Liang, primary, Pham, Lan V., additional, Newberry, Kate J., additional, Ou, Zhishuo, additional, Liang, Rong, additional, Qian, Jianfei, additional, Sun, Luhong, additional, Blonska, Marzenna, additional, You, Yun, additional, Yang, Jing, additional, Lin, Xin, additional, Rollo, Alex, additional, Tamayo, Archito T., additional, Lee, John, additional, Ford, Richard J., additional, Zhao, Xiurong, additional, Kwak, Larry W., additional, Yi, Qing, additional, and Wang, Michael, additional

Published
2013
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results